Clinical bottom line
Emerging therapies for endometriosis offer promising avenues to improve symptom control and reduce disease progression with potentially improved safety profiles compared to traditional hormonal treatments. Novel agents targeting inflammatory pathways, angiogenesis, and neurogenic mechanisms are under investigation, with some already demonstrating efficacy in reducing pain and lesion size. However, current evidence is largely from early-phase trials and systematic reviews, highlighting the need for further robust clinical data to establish long-term safety and comparative effectiveness. Individualized treatment selection remains essential, balancing efficacy, side effects, and patient preferences (Ferrero et al., 2018a; Ferrero et al., 2025).
What the evidence shows
Ferrero et al. (2018a, 2018b) provide comprehensive reviews of current and emerging pharmacotherapies for endometriosis, emphasizing that while combined oral contraceptives and progestins remain first-line, newer agents such as selective progesterone receptor modulators (SPRMs), aromatase inhibitors, and gonadotropin-releasing hormone (GnRH) antagonists show potential for improved symptom relief and lesion regression.
The 2025 review by Ferrero et al. further updates safety data, noting that emerging therapies generally have favorable tolerability but require monitoring for hypoestrogenic effects and impacts on bone density.
Guo and Wang (2008) discuss experimental drugs targeting angiogenesis and inflammation, such as anti-TNF agents and anti-VEGF therapies, which have shown efficacy in preclinical models but await clinical validation.
Rolla et al. (2023) conducted a network meta-analysis comparing subsequent therapies after fertility-preserving surgery, finding that hormonal treatments including GnRH analogs and progestins effectively reduce recurrence, with emerging agents showing comparable efficacy but limited long-term data.
Perrone et al. (2026) highlight considerations for hormonal therapies in women with migraine, a common comorbidity, underscoring the importance of individualized risk-benefit assessment.
Caveats and uncertainty
Most emerging therapies lack large-scale randomized controlled trials with long-term follow-up.
Heterogeneity in study designs, endpoints, and patient populations complicates direct comparisons.
Safety profiles, particularly regarding bone health and cardiovascular risk, require further elucidation.
Impact on fertility and pregnancy outcomes remains incompletely understood.
Cost and accessibility of novel agents may limit widespread adoption.
How this may change practice
Clinicians should remain informed about emerging therapies to offer personalized treatment options, especially for patients refractory to conventional hormonal management.
Integration of novel agents may allow for tailored approaches balancing efficacy and side effect profiles.
Multidisciplinary care including pain specialists and reproductive endocrinologists can optimize management.
Ongoing clinical trials and real-world evidence will refine guidelines and inform shared decision-making.
Patient education on emerging options and potential risks is critical to align treatment with individual goals.